Annexon Q2 net loss $49.2M; tanruprubart MAA submission Q1 2026, ARCHER II topline H2 2026

Annexon, Inc.

2025-Q2 EPS reported -$0.71

Net loss $49.2M ($0.34/share) in Q2 2025 vs $29.6M ($0.23) in Q2 2024; R&D $44.2M.
Cash and equivalents $227.0M as of June 30, 2025; runway into Q4 2026.
Tanruprubart MAA for GBS submission expected Q1 2026; FDA BLA discussions ongoing.
Vonaprument ARCHER II Phase 3 enrollment completed (659 patients); topline data H2 2026.
ANX1502 oral C1s inhibitor POC trial update in CAD anticipated by year-end 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.